| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥113.2B | ¥109.7B | +3.2% |
| Operating Income | ¥13.3B | ¥13.7B | -2.8% |
| Ordinary Income | ¥14.0B | ¥14.3B | -1.9% |
| Net Income | ¥9.5B | ¥9.8B | -2.7% |
| ROE | 4.9% | 5.2% | - |
FY2025 Q3 cumulative results show revenue of 11,321 million yen (YoY +3.2%), operating income of 1,333 million yen (YoY -2.8%), ordinary income of 1,402 million yen (YoY -1.9%), and net income of 948 million yen (YoY -2.7%). Gross profit margin remained robust at 50.0%, but increased selling, general and administrative expenses compressed operating margins. Total assets expanded to 25,771 million yen from 24,594 million yen in the prior year period, while equity strengthened to 19,599 million yen from 18,721 million yen. The company maintains strong liquidity with cash and deposits of 10,731 million yen and current ratio of 316.3%. Basic earnings per share declined slightly to 303.68 yen from 309.28 yen. The financial position remains solid with equity ratio of 76.1%, though operating profit declined despite revenue growth, indicating margin pressure from cost increases.
Revenue increased 3.2% YoY driven primarily by the Home Medical Treatment Related segment, which grew 7.7% to 5,372 million yen. Medical Gas Related segment remained essentially flat at 2,941 million yen (+0.1%), while Care Welfare Related expanded 1.9% to 896 million yen. The Nursing Home segment increased 4.7% to 263 million yen. Notably, Medical Gas Equipment Installation Related segment contracted 11.4% to 1,049 million yen. Other segments (nursing school, medical equipment) contributed 799 million yen, up 9.7% YoY.
On the profit side, operating income decreased 2.8% despite revenue growth, indicating margin compression. Segment operating profit declined from 1,278 million yen to 1,239 million yen (-3.0%). Medical Gas Related segment profit fell 29.2% to 321 million yen, and Care Welfare Related profit decreased 38.3% to 21 million yen. The Medical Gas Equipment Installation Related segment saw profit decline 4.9% to 157 million yen. However, Home Medical Treatment Related segment profit grew 17.5% to 743 million yen, partially offsetting other declines. The Nursing Home segment loss improved from -6 million yen to -3 million yen. Selling, general and administrative expenses increased, rising from approximately 3,888 million yen to 4,332 million yen (calculated from gross profit minus operating income), representing 38.3% of revenue versus 35.4% in the prior period.
Ordinary income declined 1.9% to 1,402 million yen, with the gap between operating and ordinary income representing 69 million yen in non-operating net income, comprising primarily dividend income of 48 million yen and interest income of 26 million yen. Net income decreased 2.7% to 948 million yen, with the effective tax rate at approximately 31.5%. No material extraordinary items or impairment losses were reported. This represents a revenue up/profit down pattern, driven by segment mix shifts and cost pressures outweighing top-line growth.
The Home Medical Treatment Related segment is the core business with 47.4% of total revenue (5,372 million yen) and 59.9% of total segment operating profit (743 million yen), delivering a segment operating margin of 13.8%. This segment demonstrated strong performance with revenue growth of 7.7% and operating profit growth of 17.5% YoY, indicating improving operational efficiency and scale benefits.
The Medical Gas Related segment contributed 26.0% of revenue (2,941 million yen) and 25.9% of segment operating profit (321 million yen), with an operating margin of 10.9%. However, this segment experienced significant profit deterioration with operating income declining 29.2% despite flat revenue, suggesting pricing pressure or cost increases specific to this business line.
The Medical Gas Equipment Installation Related segment accounted for 9.3% of revenue (1,049 million yen) and 12.7% of segment profit (157 million yen), delivering the highest margin at 15.0%. Revenue contracted 11.4% with operating profit declining 4.9%, indicating better cost management despite revenue headwinds.
The Care Welfare Related segment represented 7.9% of revenue (896 million yen) and 1.7% of segment profit (21 million yen), with a thin margin of 2.3%. Operating profit declined sharply by 38.3%, indicating structural profitability challenges in this segment.
The Nursing Home segment contributed 2.3% of revenue (263 million yen) but remained in operating loss of -3 million yen, though the loss narrowed from -6 million yen in the prior year. This segment continues to face profitability challenges despite modest revenue growth.
[Profitability] ROE of 4.8% remains below the company's historical levels and indicates moderate capital efficiency. Net profit margin of 8.4% compares favorably but declined slightly from prior year. Operating margin of 11.8% (1,333 million yen operating income on 11,321 million yen revenue) contracted from 12.5% in the prior period, reflecting cost pressures. EBIT margin of 11.8% aligns with operating margin given minimal non-recurring items. Gross profit margin maintained at 50.0% demonstrates strong pricing power and product mix. [Cash Quality] Cash and deposits of 10,731 million yen provide 24.2x coverage of short-term debt obligations. Working capital of 9,602 million yen indicates ample liquidity buffer. [Investment Efficiency] Asset turnover of 0.439 reflects moderate asset productivity, with total assets of 25,771 million yen generating 11,321 million yen in quarterly revenue. Receivables turnover at 88 days indicates extended collection periods. Inventory increased 75.4% YoY to 313 million yen, raising inventory management concerns. [Financial Health] Equity ratio of 76.1% significantly exceeds industry norms and demonstrates conservative capital structure. Current ratio of 316.3% and quick ratio of 309.3% indicate robust short-term liquidity. Debt-to-equity ratio of 0.31x reflects minimal leverage. Total liabilities of 6,172 million yen against equity of 19,599 million yen provides substantial balance sheet cushion. Financial leverage of 1.31x indicates conservative use of debt financing.
Cash and deposits increased 4.0% YoY to 10,731 million yen from 10,317 million yen, indicating continued cash accumulation despite profit decline. The increase of 414 million yen suggests operating activities generated sufficient cash to maintain liquidity. Accounts receivable expanded to 2,720 million yen from 2,545 million yen, representing 6.9% growth that outpaced revenue growth of 3.2%, signaling extended payment terms or collection delays as indicated by the 88-day DSO metric. Inventory surged 75.4% to 313 million yen from 179 million yen, representing significant working capital investment that likely absorbed substantial operating cash. Accounts payable increased to 1,161 million yen from 1,078 million yen (+7.7%), suggesting effective utilization of trade credit. Investment securities expanded 27.8% to 3,792 million yen from 2,967 million yen, indicating deployment of 825 million yen into financial assets during the period. This substantial investment activity, combined with inventory buildup totaling approximately 959 million yen in incremental working capital and investments, explains the modest cash increase despite profit generation. The cash-to-short-term liabilities coverage ratio stands at approximately 2.4x, providing comfortable liquidity headroom. Total assets increased 4.8% to 25,771 million yen, with the growth funded primarily through retained earnings as equity increased 4.7% to 19,599 million yen.
Ordinary income of 1,402 million yen versus operating income of 1,333 million yen reflects non-operating net income of 69 million yen, comprising primarily equity method gains, dividend income, and interest income. Reported non-operating income of 88 million yen includes interest and dividend income of 48 million yen and interest income of 26 million yen as key components. Non-operating income represents 0.8% of revenue, consisting mainly of investment returns from the expanded securities portfolio of 3,792 million yen. The stable gross margin of 50.0% and absence of impairment losses or extraordinary items indicate core earnings quality is maintained. However, without disclosed operating cash flow data, the cash conversion quality of reported earnings cannot be directly verified. The receivables growth outpacing revenue growth by 3.7 percentage points and the 75.4% surge in inventory raise concerns about working capital management and potential overstatement of earnings quality. The effective tax rate of approximately 31.5% aligns with statutory expectations. Interest coverage of 113.08x indicates minimal financial risk from debt obligations. The substantial increase in investment securities by 825 million yen introduces future volatility risk from mark-to-market valuation changes, though current period results show no material unrealized gains or losses reported.
The company maintains full-year guidance of revenue 15,260 million yen, operating income 2,070 million yen, ordinary income 2,140 million yen, and net income 1,476 million yen. Q3 cumulative progress rates stand at 74.2% for revenue, 64.4% for operating income, 65.5% for ordinary income, and 64.2% for net income against full-year targets. Revenue tracking aligns closely with the standard 75% Q3 benchmark, indicating full-year guidance remains achievable. However, operating income progress of 64.4% trails the 75% standard by 10.6 percentage points, suggesting Q4 must deliver 737 million yen in operating profit (55.3% of full-year target in the final quarter). This Q4 weighting appears ambitious given Q3 cumulative operating income of 1,333 million yen represents only 44.7% annual run-rate against the 2,070 million yen target. The company projects full-year YoY growth of 1.0% for revenue, 4.4% for operating income, and 3.7% for ordinary income, indicating expected Q4 improvement from Q3 trends. Full-year basic EPS guidance of 472.57 yen implies approximately 40% earnings contribution required from Q4 alone. The year-end dividend is planned at 35 yen per share for total annual dividend of 45 yen, unchanged from prior guidance.
Annual dividend is planned at 45 yen per share, comprising interim dividend of 10 yen already paid and projected year-end dividend of 35 yen. This represents maintenance of the prior year dividend level. Based on full-year net income guidance of 1,476 million yen and assuming approximately 3.1 million shares outstanding (implied from EPS guidance), the payout ratio calculates to approximately 25.3%. Using Q3 cumulative net income of 948 million yen and annualized basis, the payout ratio on current run-rate earnings would approximate 35.6%, indicating modest distribution relative to earnings generation. No share buyback activities are disclosed in the current period. The total return ratio remains equivalent to the payout ratio at approximately 25.3% based on full-year guidance, indicating conservative capital allocation weighted toward balance sheet strength. Cash and deposits of 10,731 million yen provide substantial coverage of estimated annual dividend payments of approximately 140 million yen (45 yen × 3.1 million shares), representing 76.6x coverage. The company's strong cash position and positive earnings support dividend sustainability, though the absence of disclosed operating cash flow limits full assessment of cash generation versus distribution capacity.
Receivables collection deterioration represents a primary operational risk, with DSO extending to 88 days compared to industry median of 78.91 days, indicating 9-day delay in cash conversion. Accounts receivable of 2,720 million yen growing 6.9% versus revenue growth of 3.2% signals potential credit quality concerns or extended payment term concessions that could pressure cash flow and require increased working capital financing.
Inventory management deterioration poses working capital risk, with inventory surging 75.4% to 313 million yen despite revenue growth of only 3.2%. This dramatic buildup either reflects strategic stocking ahead of anticipated demand or indicates excess/slow-moving inventory risk. The inventory increase absorbed approximately 134 million yen of working capital and suggests potential future write-down risk or pricing pressure to clear stock.
Segment profitability pressure in Medical Gas Related business threatens earnings stability, with operating profit declining 29.2% to 321 million yen despite flat revenue. This core segment representing 26% of revenue shows margin compression from 15.4% to 10.9%, indicating structural cost pressures, competitive pricing dynamics, or unfavorable product mix shifts that may persist and spread to other segments if underlying causes are not addressed.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE of 4.8% significantly underperforms the trading industry median of 6.4% (IQR: 2.4%-9.9%), placing the company in the lower performance quartile. Net profit margin of 8.4% substantially exceeds the industry median of 2.7% (IQR: 1.3%-6.0%), indicating superior pricing power and cost structure relative to peers. Operating margin of 11.8% significantly outperforms the industry median of 3.2% (IQR: 1.7%-4.9%), demonstrating strong operational efficiency despite recent margin compression.
Financial Health: Equity ratio of 76.1% far exceeds the industry median of 46.4% (IQR: 39.6%-52.6%), reflecting highly conservative capital structure with minimal financial risk. Current ratio of 316.3% substantially surpasses the industry median of 1.88x (IQR: 1.64x-2.38x), indicating superior liquidity positioning. Financial leverage of 1.31x falls well below the industry median of 2.13x (IQR: 1.87-2.46), confirming conservative balance sheet approach.
Efficiency: Asset turnover of 0.439 significantly underperforms the industry median of 1.00 (IQR: 0.62-1.20), indicating lower asset productivity and suggesting room for improvement in capital deployment. Receivables turnover of 88 days compares unfavorably to the industry median of 78.91 days (IQR: 67.47-103.26 days), though remains within the interquartile range. Revenue growth of 3.2% aligns with industry median of 5.0% (IQR: -5.0%-7.8%), representing moderate but stable growth performance.
Overall, the company demonstrates superior profitability margins and financial stability relative to trading industry peers, but lags in capital efficiency metrics, resulting in below-median ROE despite strong profit margins.
※ Industry: Trading (19 companies), Comparison: FY2025 Q3, Source: Proprietary analysis
The company exhibits a distinctive profile of exceptional profit margins and financial conservatism combined with below-average capital efficiency. Net profit margin of 8.4% and operating margin of 11.8% significantly exceed industry medians of 2.7% and 3.2% respectively, demonstrating competitive advantages in pricing power and cost management within the medical gas and home medical treatment sectors. However, ROE of 4.8% trails the industry median of 6.4% due to conservative financial leverage of 1.31x versus industry median of 2.13x and asset turnover of 0.439 versus industry median of 1.00, indicating substantial untapped potential for enhanced shareholder returns through improved capital deployment.
Working capital management deterioration emerges as a critical trend requiring attention. Inventory surged 75.4% while revenue grew only 3.2%, and receivables collection extended to 88 days versus the 79-day industry median. These trends absorbed significant cash and compressed asset turnover, directly contributing to the operating profit decline of 2.8% despite revenue growth. The operational data suggests Q4 faces substantial pressure to meet full-year guidance, requiring 55.3% of annual operating profit in the final quarter against historical quarterly patterns.
The Home Medical Treatment Related segment demonstrates strong momentum with 7.7% revenue growth and 17.5% profit growth, supporting segment margin expansion to 13.8%, while the Medical Gas Related segment experienced sharp 29.2% profit decline despite stable revenue, indicating business-specific challenges requiring management attention. Cash and investment securities total 14,523 million yen (56.4% of total assets), providing substantial financial flexibility for strategic investments, dividend sustainability (25.3% payout ratio provides ample headroom), or potential capital efficiency initiatives, though current deployment toward passive investments rather than productive assets constrains ROE performance.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.